Veradermics

Veradermics

Veradermics launched in 2018 from New Haven, Connecticut, with Reid Waldman, a practicing dermatologist, and hair-loss researcher Brett King at the scientific helm. The company targets hair-growth disorders — chiefly androgenetic alopecia — a market long dominated by topical minoxidil and finasteride pills carrying a known side-effect profile. Their founding thesis argues that dermatology's most common aesthetic conditions remain under-treated by systemic, oral therapeutics developed to modern regulatory standards. The pipeline hinges on VDPHL01, a non-hormonal oral therapy shown in a 2023 pivotal Phase II/III trial to meaningfully regrow hair without the sexual side effects associated with existing androgen-modulating drugs (per the firm's public disclosures). The company deploys a clinical-stage biotech strategy, funding FDA-track programs rather than building commercial infrastructure. Its positioning spans dermatology, endocrinology, and aesthetic medicine — a crossover few pure-play pharma sponsors attempt — with an initial addressable market of over 80 million US adults experiencing pattern hair loss. Veradermics closed a $75 million Series B in late 2024 co-led by Suvretta Capital and Longitude Capital, with Novo Holdings and Connecticut Innovations participating (per public filings). Waldman remains President and CEO; King — the Yale dermatologist who first repurposed JAK inhibitors for alopecia areata — guides science. The Series B proceeds target the VDPHL01 New Drug Application submission, projected in 2025, and fund pipeline expansion into areata and telogen effluvium variants. The company operates from the Elm City's life-science corridor, drawing talent from Yale's dermatology bench without yet establishing additional physical offices. The structural difference is Waldman's dual role as a practicing physician and biotech CEO — giving Veradermics a direct link to the clinical realities of patient demand and prescription-pattern inertia that pure-science founders often miss. This practitioner-to-sponsor architecture mirrors the rare path carved by physician-founded dermatology companies like Arcutis, where the founder's waiting room informs the FDA submission. If VDPHL01 secures approval, it would be the first new oral mechanism for androgenetic alopecia since finasteride's 1997 entry.